Market Risers: Actual Experience, AFC Energy, AstraZeneca, British American Tobacco

Broker Ratings

Shares of Actual Experience ticker lookup code: LON:ACT has increased 9.09% or 10 points in today’s trading session so far. Investors have stayed positive throughout the trading session. The periods high has already touched 120 and a low of 116.33. The amount of shares exchanged has so far reached 4,569 with the daily average traded share volume around 61,692. The 52 week high is 120 some 10 points difference from the previous close and the 52 week low at 20 making a difference of 90 points. Actual Experience now has a 20 SMA at 88.46 and the 50 day SMA of 95.17. Market capitalisation is now £57.18m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Actual Experience being recorded at Monday, December 7, 2020 at 9:36:49 AM GMT with the stock price trading at 120 GBX.

The stock price for AFC Energy with ticker code: LON:AFC has gained 3.73% or 1.34 points throughout the session so far. Buyers are a positive bunch throughout the session. The periods high has already touched 38.85 meanwhile the session low reached 36.15. The number of shares traded by this point in time totalled 2,785,548 with the average number of shares traded daily being 9,439,565. The stock 52 week high is 40.85 which comes in at 4.95 points in difference to the previous days close of business and a 52 week low sitting at 9 which is a variance of 26.9 points. AFC Energy has a 20 day moving average of 29.23 and now a 50 day SMA of 22.84. This puts the market capitalisation now at £251.76m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for AFC Energy being recorded at Monday, December 7, 2020 at 12:26:44 PM GMT with the stock price trading at 37.24 GBX.

Shares of AstraZeneca found using EPIC: LON:AZN has risen 2.27% or 181 points throughout today’s trading session so far. Market buyers have stayed positive throughout the session. The periods high figure was 8185 and hitting a low of 8052. Volume total for shares traded during this period was 701,516 with the average number of shares traded daily being 2,668,640. A 52 week high for the stock is 10120 about 2162 points different to the previous business close and a 52 week low sitting at 5871 which is a variance of 2087 points. AstraZeneca now has a 20 moving average of 8297.33 and now a 50 day SMA of 8309.43. Market capitalisation for the company is £106,809.36m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Monday, December 7, 2020 at 12:29:57 PM GMT with the stock price trading at 8139 GBX.

Stock in British American Tobacco ADS Common Stock with EPIC code: LON:BATS has stepped up 4.24% or 115.5 points throughout today’s trading session so far. Traders are a positive bunch during the trading session. The high for the period has reached 2852.5 while the low for the session was 2737. The number of shares traded by this point in time totalled 1,282,170 while the daily average number of shares exchanged is 4,696,063. A 52 week share price high is 3507 around 786 points difference from the previous close and the 52 week low at 2362.5 a difference of some 358.5 points. BRITISH AMERICAN TOBACCO ADS Common Stock now has a 20 simple moving average of 2756.04 with a 50 day moving average at 2699.75. The current market capitalisation is £65,076.20m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for BRITISH AMERICAN TOBACCO ADS Common Stock being recorded at Monday, December 7, 2020 at 12:29:57 PM GMT with the stock price trading at 2836.5 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio.

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...

British American Tobacco updates South Africa branch register dividend details

British American Tobacco Plc declared an interim dividend of 245.04p per share for 2026, paid in four quarterly instalments. The August 2026 dividend of 61.26p per share is payable on 14 August 2026 to shareholders on the UK and South Africa registers. For South African shareholders, the dividend converts to 1,331.05115 cents per share before tax.

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer.

British American Tobacco confirms closed period buyback arrangement

British American Tobacco Plc has entered into an irrevocable buyback agreement with UBS for the closed period to 29 July 2026.

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer.

Search